Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Anker

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
European Journal of Heart Failure|November 10, 2025
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular PharmacotherapyGianluigi Savarese, Felix Lindberg, Antonio Cannata, et al.
Nature Biotechnology|December 28, 2020
Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19Saskia Trump, Soeren Lukassen, Markus S Anker, et al.
European Journal of Heart Failure|October 2, 2020
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Christian Mueller, Jelena Čelutkienė, et al.
Faraday Discussions|December 18, 2024
Discovering synthesis targets: general discussionAndy S Anker, Alán Aspuru-Guzik, Tim Bechtel, et al.
European Journal of Heart Failure|July 18, 2023
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D Anker, Muhammad Shariq Usman, Markus S Anker, et al.
European Journal of Heart Failure|April 19, 2024
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular FunctionPietro Ameri, Valentina Mercurio, Piero Pollesello, et al.
European Journal of Heart Failure|April 29, 2025
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trialsStefan D Anker, Tim Friede, Javed Butler, et al.
Chemical Science|December 12, 2024
Assessment of fine-tuned large language models for real-world chemistry and material science applicationsJoren Van Herck, María Victoria Gil, Kevin Maik Jablonka, et al.
JAMA|March 30, 2025
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical TrialStefan D Anker, Tim Friede, Javed Butler, et al.
European Journal of Heart Failure|July 5, 2020
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)Jelena Čelutkienė, Radek Pudil, Teresa López-Fernández, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
European Journal of Heart Failure|November 10, 2025
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular PharmacotherapyGianluigi Savarese, Felix Lindberg, Antonio Cannata, et al.
Nature Biotechnology|December 28, 2020
Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19Saskia Trump, Soeren Lukassen, Markus S Anker, et al.
European Journal of Heart Failure|October 2, 2020
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Christian Mueller, Jelena Čelutkienė, et al.
Faraday Discussions|December 18, 2024
Discovering synthesis targets: general discussionAndy S Anker, Alán Aspuru-Guzik, Tim Bechtel, et al.
European Journal of Heart Failure|July 18, 2023
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D Anker, Muhammad Shariq Usman, Markus S Anker, et al.
European Journal of Heart Failure|April 19, 2024
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular FunctionPietro Ameri, Valentina Mercurio, Piero Pollesello, et al.
European Journal of Heart Failure|April 29, 2025
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trialsStefan D Anker, Tim Friede, Javed Butler, et al.
Chemical Science|December 12, 2024
Assessment of fine-tuned large language models for real-world chemistry and material science applicationsJoren Van Herck, María Victoria Gil, Kevin Maik Jablonka, et al.
JAMA|March 30, 2025
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical TrialStefan D Anker, Tim Friede, Javed Butler, et al.
European Journal of Heart Failure|July 5, 2020
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)Jelena Čelutkienė, Radek Pudil, Teresa López-Fernández, et al.
Pageof 19